查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750708

遗传性癌症检测市场规模、份额、趋势分析报告：按癌症、技术、检测类型、最终用途、地区、细分市场预测，2025-2030 年

Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

遗传性癌症检测市场的成长与趋势

根据Grand View Research, Inc.的最新报告，全球遗传性癌症检测市场规模预计到2030年将达到94.529亿美元，2025年至2030年期间的复合年增长率为12.9%。

政府支持、医疗资金以及直接面向消费者 (DTC) 的基因检测平台的成长推动了该市场的发展。遗传性癌症占所有癌症的 10%，其余 90% 为散发性癌症。我们需要满足日益增长的遗传性癌症检测需求，这可以透过政府措施和资金投入来实现，以满足医疗保健需求。政府旨在预防癌症和基因研究的倡议和资金正在显着推动遗传性癌症检测市场的发展。

许多国家已出台政策，将基因检测作为其癌症风险评估计划的一部分，并通常提供检测费用的财务支持。例如，美国国家综合癌症网络 (NCCN) 于 2025 年 1 月推出了一项新资源，旨在为个人提供有关遗传性和遗传性癌症风险的最新建议。该指南重点关注遗传性乳癌、卵巢癌、胰腺癌和前列腺癌，也可透过应用程式取得。该指南提供了清晰易懂的指导，指导人们如何评估和检测可能增加癌症风险的遗传基因突变。讯息以清晰易懂的方式呈现。

遗传性癌症检测的监管核准确保了用于评估癌症风险的基因检测符合准确性、安全性和可靠性的严格标准。 FDA 将这些检测归类为医疗设备，必须经过全面评估才能核准上市。 2023 年 9 月，美国食品药物管理局(FDA) 首次核准了一种用于评估多种癌症遗传易感性的 DNA 检测。这项里程碑式的核准允许透过次世代定序 (NGS) 存取与多种癌症（包括乳癌、卵巢和结直肠癌）风险升高相关的多个突变基因，以提供高灵敏度、快速和准确的见解。透过识别这些遗传突变，该检测为个人提供了有价值的信息，以指南早期发现、预防措施和个性化治疗计划。这项核准标誌着基因检测和癌症预防领域的一个重要里程碑，使个人能够采取积极主动的措施来管理自己的健康。

各国政府意识到基因检测可能带来医疗保健领域的革命，已启动多项倡议，旨在将基因检测服务整合到公共卫生基础设施中。美国国家癌症实验室迈出了重要一步，向乔治城大学伦巴第综合癌症中心和新泽西州罗格斯大学癌症实验室的研究人员提供了320万美元的津贴。这项津贴将支持一项为期五年的研究，该研究将招募428名符合国家遗传性癌症检测指南的黑人癌症患者参加随机对照试验，并评估这些干预措施对基因教育参与度、检测接受度、知情决策和社会心理结果的影响。透过消除基因检测的障碍并吸收社区意见，该研究旨在提高筛检的可近性，改善癌症的医疗管理，并最终促进癌症治疗中的健康公平。

市场上出现了 Myriad Genetics, Inc.、Bio-Rad Laboratories、F. HOFFMANN-LA ROCHE LTD 和 Illumina, Inc. 等主要参与企业的活动。这些参与企业正在积极寻求美国FDA的产品核可，以满足全球客户的需求。例如，2024 年 6 月，Myriad Genetics, Inc. 宣布正在进行的创新：MyChoice CDx HRD 和 BRACAnalysis CDx 种系伴随诊断测试，以透过研究合作加强产品系列。此外，Myriad 已启动多项合作，探索 MRD 在各种癌症中的潜力。此外，精准医疗癌症线上筛检工具的开发将使病患教育能够改善结果。例如，2025 年 1 月，Myriad Genetics, Inc. 发表了一项研究表明，结合线上筛检工具和基因教育，患者更有可能完成遗传性癌症检测。这种方法强调了数位工具和教育在提高参与度和对癌症风险评估基因检测的兴趣方面的重要性。

因此，基因检测技术的进步、政府倡议和资金的增加以及监管核准的加速正在推动早期检测和疾病预防市场的成长。

遗传性癌症检测市场报告重点

  • 按癌症类别划分，乳癌将在2024年占据最大的收益占有率，达到12.45%。由于次世代定序仪(NGS) 和人工智慧 (AI) 的进步，遗传性乳癌检测市场正在不断扩大，这些技术能够实现全面的风险评估。认知度的提高、政府的措施以及保险覆盖范围的扩大，进一步推动了该检测的普及。这些技术创新正在促进早期发现和个人化预防策略，从而改善患者的预后。
  • 从技术角度来看，分子检测将占据市场主导地位，到2024年将占据56.36%的最大份额。由于癌症盛行率的上升以及新一代快速基因分析技术的进步，遗传性癌症检测市场中的分子检测细分市场正在不断扩大。这些技术提高了诊断的准确性，并促进了个人化治疗策略的实施。此外，人们意识的增强和保险覆盖率的提高也推动了分子检测的普及。
  • 根据测试类型，预测性基因检测预计将成为遗传性癌症检测市场的主导部分，到 2024 年将占据 66.49% 的份额。遗传疾病盛行率的上升和对预防性医疗保健的日益重视进一步推动了预测性基因检测的采用。
  • 从最终用途来看，到2024年，医院将占据最大的市场份额，达到55.11%，并在其他细分市场中保持成长。医院正在与研究型大学合作，以推动该市场的成长。
  • 由于许多主要市场参与企业的存在、次世代定序(NGS) 的进步、对遗传风险的认识不断提高以及保险覆盖范围的扩大，北美在全球市场占据主导地位。
  • 由于主要企业利用创新技术进行扩张以及诊断研究能力的加速，亚太地区预计将以最快的速度成长，2025 年至 2030 年期间的复合年增长率达到 14.3%。

目录

第一章调查方法与范围

第二章执行摘要

3. 遗传性癌症检测市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 遗传性癌症检测市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析

第四章遗传性癌症检测市场：按癌症类型进行的估计和趋势分析

  • 细分仪表板
  • 遗传性癌症检测市场：癌症变异分析
  • 遗传性癌症检测市场规模及趋势分析（依癌症类型，2018-2030）
  • 2018-2030年市场规模、预测及趋势分析
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 卵巢癌
  • 摄护腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宫癌
  • 胰臟癌
  • 其他的

第五章遗传性癌症检测市场：依技术、估计和趋势分析

  • 2024 年及 2030 年技术市场占有率
  • 细分仪表板
  • 全球遗传性癌症检测市场（依技术格局）
  • 2018-2030年市场规模、预测及趋势分析
  • 细胞遗传学
  • 生化
  • 分子检测

第六章 测试类型市场：按测试类型进行的估计和趋势分析

  • 2024 年和 2030 年测试类型市场占有率
  • 细分仪表板
  • 全球遗传性癌症检测市场按检测类型展望
  • 2018-2030年市场规模、预测及趋势分析
  • 预测测试
  • 诊断测试

第七章 最终用途市场：依最终用途的估算与趋势分析

  • 2024 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 全球遗传性癌症检测市场（依最终用途）展望
  • 2018-2030年市场规模、预测及趋势分析
  • 诊断中心
  • 医院
  • 诊所

第 8 章：遗传性癌症检测市场：区域、估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 2024年主要企业市场占有率分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-588-5

Hereditary Cancer Testing Market Growth & Trends:

The global hereditary cancer testing market size is expected to reach of USD 9,452.9 million by 2030, and is projected to grow at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is accelerating, due to government support and healthcare funding and growth of direct-to-consumer (DTC) genetic testing platforms. Hereditary cancer accounts overall to 10% and remaining 90% is sporadic cancer. There arises a need to address this growing demand of hereditary cancer which may be possible by government initiatives and funding to meet the healthcare demand. Government initiatives and funding aim at cancer prevention and genetic research significantly drive the hereditary cancer testing market.

Many countries have introduced policies that promote genetic testing as part of cancer risk assessment programs, often providing financial support for testing costs. For example, the National Comprehensive Cancer Network (NCCN), in January 2025, released a new resource designed to provide individuals with the most up-to-date recommendations on hereditary and familial cancer risks. These guidelines focus on hereditary breast, ovarian, pancreatic and prostate cancer which is available also through and app. It offers clear, easy-to-understand guidance on how to assess and test for inherited genetic mutations that may increase the risk of cancer. The information is available in a straightforward and accessible way for better comprehension.

Regulatory approvals for hereditary cancer testing ensures that genetic tests used to assess cancer risk meet rigorous standards for accuracy, safety, and reliability. The FDA classifies these tests as medical devices, and they must undergo thorough evaluation before receiving approval for market use. U.S. Food and Drug Administration (FDA) in September 2023, granted its first-ever marketing authorization for a DNA test designed to assess the genetic predisposition to multiple types of cancer. This groundbreaking approval can access multiple variant genes through next generation sequencing (NGS) which are linked to an increased risk of several cancers, including breast, ovarian, and colorectal cancers to provide insights with sensitivity, speed and accuracy. By identifying these inherited genetic mutations, the test provides individuals with valuable information to guide early detection, preventive measures, and personalized treatment plans. This approval marks a significant milestone in the field of genetic testing and cancer prevention, empowering individuals to take proactive steps toward managing their health.

Recognizing the potential of genetic testing in revolutionizing healthcare, government launches several initiatives aimed at integrating genetic services into the public health infrastructure. One significant stride taken by National Cancer Institute that awarded USD 3.2 million grant to researchers at Georgetown University's Lombardi Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. This funding supports a five-year study enrolling 428 Black cancer patients who meet national guidelines for hereditary cancer testing into a randomized controlled trial and will evaluate the impact of these interventions on genetic education engagement, testing uptake, informed decision-making, and psychosocial outcomes. By addressing barriers to genetic testing and incorporating community input, the research aimed at improving access to screening, and medical management of cancers, ultimately advancing health equity in oncology care.

The market has been witnessing activity of the key players such as Myriad Genetics, Inc., Bio-Rad Laboratories, F. HOFFMANN-LA ROCHE LTD and Illumina, Inc. these players are actively engaged in seeking product approvals from USFDA to meet the need of global customers. For instance, in June 2024, Myriad Genetics, Inc, announced its ongoing innovations: MyChoice CDx HRD and BRACAnalysis CDx Germline Companion Diagnostic Tests for enhancing its product portfolio through research collaborations. Additionally, Myriad has initiated multiple research collaborations to investigate the potential of MRD in various cancers. Furthermore, developments in precision medicine online screening tools for cancer enable patient education for improved outcomes. For instance, in January 2025, Myriad Genetics, Inc, announced a study showing that patients were more likely to complete hereditary cancer testing when using an online screening tool combined with genetic education. This approach highlights the importance of digital tools and education in increasing engagement and participation in genetic testing for cancer risk assessment.

Thus, technological advancements in genetic testing, growing government initiatives and funding support and accelerated regulatory approvals are boosting the market growth for early detection and disease prevention.

Hereditary Cancer Testing Market Report Highlights:

  • Based on cancer, breast cancer accounted for largest revenue share of 12.45% in 2024. The hereditary breast cancer testing market is expanding due to advancements in next-generation sequencing (NGS) and artificial intelligence (AI), enabling comprehensive risk assessments. Increased awareness, government initiatives, and expanded insurance coverage further drive adoption. These innovations facilitate early detection and personalized prevention strategies, enhancing patient outcomes.
  • Based on technology, molecular testing dominated the market and accounted for the largest share of 56.36% in 2024.The molecular testing segment in the hereditary cancer testing market is expanding due to rising prevalence of cancer, advancements in next-generation and quick genetic analysis. These technologies enhance diagnostic accuracy and facilitate personalized treatment strategies. Additionally, increased awareness and insurance coverage are driving adoption.
  • Based on test type, in 2024, predictive genetic testing emerged as the dominant segment in the hereditary cancer testing market, capturing 66.49% of the share. The increasing prevalence of genetic disorders and a growing emphasis on preventive healthcare further drive the adoption of predictive genetic tests.
  • Based on end use, hospitals dominated the end-use segments with the largest market share of 55.11% in 2024 and were the fastest growing among the other segments over the period. Hospitals in collaboration with research universities are boosting the growth for this market.
  • North America dominated the global market due to the presence of a large number of major market players, advancements in next-generation sequencing (NGS), increasing awareness of genetic risks, and expanded insurance coverage.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 14.3% from 2025 to 2030, due to expansion by key players with innovative technologies coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2018 to 2030 (USD Million)
  • 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Test type Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. End Use Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Myriad Genetics, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Invitae Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Qiagen NV
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Abbott Laboratories
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. EUROFINS SCIENTIFIC
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. F. HOFFMANN-LA ROCHE LTD
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Services benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Illumina, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Services benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Hereditary cancer testing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 4 North America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 6 North America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 7 U.S Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 8 U.S Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 10 U.S Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 11 Canada Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 12 Canada Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 14 Canada Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 15 Mexico Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 16 Mexico Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 19 Europe Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 20 Europe Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 22 Europe Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 23 UK Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 24 UK Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 25 UK Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 26 UK Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 27 Germany Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 28 Germany Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Germany Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Germany Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 31 France Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 32 France Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 33 France Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 34 France Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 35 Italy Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 36 Italy Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Italy Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Italy Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 39 Spain Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 40 Spain Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Spain Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Spain Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Denmark Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 44 Denmark Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Denmark Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 47 Sweden Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 48 Sweden Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Sweden Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 51 Norway Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 52 Norway Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Norway Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Norway Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 59 Japan Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 60 Japan Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Japan Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Japan Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 63 China Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 64 China Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 65 China Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 66 China Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 67 India Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 68 India Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 69 India Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 70 India Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 71 Australia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 72 Australia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 73 Australia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 74 Australia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 75 South Korea Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 76 South Korea Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 77 South Korea Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 78 South Korea Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 79 Thailand Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 80 Thailand Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 81 Thailand Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 82 Thailand Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 83 Latin America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 84 Latin America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 85 Latin America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 86 Latin America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 87 Brazil Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 88 Brazil Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 89 Brazil Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 90 Brazil Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 91 Argentina Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 92 Argentina Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 93 Argentina Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 94 Argentina Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 95 MEA Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 96 MEA Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 97 MEA Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 98 MEA Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 99 South Africa Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 100 South Africa Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 101 South Africa Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 102 South Africa Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 107 UAE Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 108 UAE Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 109 UAE Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 110 UAE Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 111 Kuwait Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 112 Kuwait Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 113 Kuwait Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 114 Kuwait Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Hereditary cancer testing market: market outlook
  • Fig. 14 Hereditary cancer testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Hereditary cancer testing market driver impact
  • Fig. 20 Hereditary cancer testing market restraint impact
  • Fig. 21 Hereditary cancer testing market strategic initiatives analysis
  • Fig. 22 Hereditary cancer testing market: Cancer movement analysis
  • Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig. 24 Hereditary cancer Testing market estimates and forecast, 2018 - 2030
  • Fig. 25 Hereditary cancer testing Market: Technology movement analysis
  • Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig. 27 Cytogenetic market estimates and forecasts, 2018 - 2030
  • Fig. 28 Biochemical market estimates and forecasts,2018 - 2030
  • Fig. 29 Molecular Testing market estimates and forecasts,2018 - 2030
  • Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig. 32 Predictive Testing market estimates and forecasts, 2018 - 2030
  • Fig. 33 Diagnostic Testing market estimates and forecasts, 2018 - 2030
  • Fig. 34 Hereditary cancer testing Market: End Use movement analysis
  • Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig. 36 Diagnostic Centers market estimates and forecasts, 2018 - 2030
  • Fig. 37 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 38 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global Hereditary cancer testing market: Regional movement analysis
  • Fig. 40 Global Hereditary cancer testing market: Regional outlook and key takeaways
  • Fig. 41 Global Hereditary cancer testing market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America
  • Fig. 49 North America market estimates and forecasts, 2018 - 2030
  • Fig. 50 U.S.
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 52 Canada
  • Fig. 53 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 54 Mexico
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 56 Europe
  • Fig. 57 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 58 UK
  • Fig. 59 UK market estimates and forecasts, 2018 - 2030
  • Fig. 60 Germany
  • Fig. 61 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 62 France
  • Fig. 63 France market estimates and forecasts, 2018 - 2030
  • Fig. 64 Italy
  • Fig. 65 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 66 Spain
  • Fig. 67 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 68 Denmark
  • Fig. 69 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 70 Sweden
  • Fig. 71 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 72 Norway
  • Fig. 73 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 74 Asia Pacific
  • Fig. 75 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 76 China
  • Fig. 77 China market estimates and forecasts, 2018 - 2030
  • Fig. 78 Japan
  • Fig. 79 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 80 India
  • Fig. 81 India market estimates and forecasts, 2018 - 2030
  • Fig. 82 Thailand
  • Fig. 83 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 84 South Korea
  • Fig. 85 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 86 Australia
  • Fig. 87 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 88 Latin America
  • Fig. 89 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 90 Brazil
  • Fig. 91 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 92 Argentina
  • Fig. 93 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 94 Middle East and Africa
  • Fig. 95 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 South Africa
  • Fig. 97 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 98 Saudi Arabia
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 100 UAE
  • Fig. 101 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 102 Kuwait
  • Fig. 103 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 104 Market share of key market players - Hereditary cancer testing market